Rapid Dose Therapeutics and McMaster University Initiate QuickStrip™ COVID-19 Vaccine Research With Immediate Impact

— Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian Life Sciences company focused on innovative drug and active ingredient delivery solutions, is pleased to announce it has begun COVID-19 vaccine research in conjunction with McMaster University and the team lead by Drs. Alex Adronov, James Mahony, and Mark Larché. The federally-funded project tests the useContinue reading “Rapid Dose Therapeutics and McMaster University Initiate QuickStrip™ COVID-19 Vaccine Research With Immediate Impact”

Relevium Technologies and H-Source Holdings Partner for the Strategic Development and Global Supply of Personal Protective Equipment

— Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce it has entered into a Letter of Intent (“LOI”) with H-Source Holdings, a leading secure and trusted Personal Protective Equipment (“PPE”) platform, to partner in the development, strategic sourcing and supply of global PPE requirements dueContinue reading “Relevium Technologies and H-Source Holdings Partner for the Strategic Development and Global Supply of Personal Protective Equipment”

Relevium Provides Regulatory Update Pursuant to Temporary Relief Granted by Regulators Due to COVID-19

— Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to provide a regulatory update pursuant to the temporary relief granted by regulators due to COVID-19. On June 2, 2020 The Company issued a regulatory update and the delayed filing of the third quarter of fiscal year endingContinue reading “Relevium Provides Regulatory Update Pursuant to Temporary Relief Granted by Regulators Due to COVID-19”

Relevium Expands CleanCare Offering as International Organizations Call for Increased Institutional and Government Stockpile of Supplies

— Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has expanded and continues to expand its CleanCare™ product line as it prepares to address increased government and institutional demand for disinfection supplies in preparation for a potential second wave of COVID-19. On June 18,Continue reading “Relevium Expands CleanCare Offering as International Organizations Call for Increased Institutional and Government Stockpile of Supplies”

North Bud Farms Provides Corporate Update

Divestment of U.S. Operations and Failure-to-File Cease Trade Order Issued THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, June 02, 2020 (GLOBE NEWSWIRE) — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) provides shareholdersContinue reading “North Bud Farms Provides Corporate Update”

FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis

TORONTO, June 3, 2020 /CNW/ – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA)  to treat COVID-19, the disease caused by the SARS-CoV-2 virus.Continue reading “FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis”

Alcanna Reports 28% Growth in Sales and Gross Margin and the Sale of the Alaska Operations

EDMONTON, Alberta, June 01, 2020 (GLOBE NEWSWIRE) — Alcanna Inc. (the “Company” or “Alcanna”) (TSX: CLIQ) today reported its unaudited financial results for the three months ended March 31, 2020 and announced the sale of the Company’s Alaska operations. First Quarter Financial Results and Business Update During the first quarter of 2020, Alcanna continued toContinue reading “Alcanna Reports 28% Growth in Sales and Gross Margin and the Sale of the Alaska Operations”

Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial

Vancouver, British Columbia – TheNewswire – June 1, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to provide the following progress update for a Phase 2 clinical trial treatment for COVID 19. The Company is now awaiting notification by Health Canada to proceed to the Phase 2 clinical trial stage,Continue reading “Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial”

Organigram announces first phase of return-to-work strategy

Company recalls approximately 50 employees to core roles across organization MONCTON, New Brunswick–(BUSINESS WIRE)–As it continues to monitor and assess the implications of the COVID-19 pandemic, Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, has announced the first phase ofContinue reading “Organigram announces first phase of return-to-work strategy”